Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from PBMs

Billionaire Mark Cuban Says America’s Drug Pricing System Makes Patients Pay the Highest Price, ‘Make It Make Sense. It Doesn’t.’

In Senate testimony, Cuban compared pharmacy benefit managers to Amazon’s control over online sellers, arguing that PBMs use their power over formularies to keep list prices high while patients, employers, pharmacies, and taxpayers absorb the damage.

Barchart

Forced to sell medications at a loss, rural Texas pharmacies seek new survival tactics

Independent rural pharmacists are starting other businesses or selling baby shower gifts to keep their stores operating. Pharmacy deserts affect 4 million Texans.

The Texas Tribune

Trump promised lower drug prices. Here's how Congress virtually guaranteed the opposite

Mark Cuban says we wouldn't pay for potato chips like this. Congress is complicating things even more.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

TrumpRx is here and it helps, though a bit less than advertised

Trump's Republican Party continues to shift toward government market interventionism.

Fortune

Mark Cuban on the $38 trillion national debt and the absurdity of U.S. healthcare: we wouldn't pay for potato chips like this

"Can you imagine if a Pringles distributor paid full retail to Pringles and then sold to grocery stores for full retail, and then the grocery stores had to wait for a rebate?"

Fortune

Unmask The Lie: The Reason Your Local Pharmacy Always Runs Out Of Meds

Walk into your local pharmacy, and you may find the same story repeated: the medication you rely on is “out of stock.” For seniors managing...

Saving Advice

Mark Cuban says Trump’s new drug platform could succeed if it forces pharma managers to change: ‘If that happens, Trump gets all the credit’

Cuban’s Cost Plus Drugs, which he founded in 2022, similarly provides direct-to-consumer discounted pharmaceuticals.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.

Benzinga

Reform Refill: Has Scott Wiener Convinced Gov. Newsom to Rein in Prescription Middlemen?

Why a state senator may finally win his battle against powerful pharmacy benefit managers.

Capital & Main

How Democrats can pull off a win now

There is no need to wait for the next election

Salon

Trump has promised to 'knock out' pharmacy benefit managers. How the drug middlemen became a $557 billion industry that its customers love to hate

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

Fortune

FTC Report Reveals Pbms Inflated Drug Prices For Profit

FTC report exposes PBMs inflating drug prices, sparking debate on industry oversight.

Top News

GOP Spending Bill Excludes Major Changes To Pharmacy Benefit Managers

GOP spending bill proposal excludes reforms for pharmacy benefit managers (PBMs) despite bipartisan expectations.

Top News

What are pharmacy benefit managers? A health economist explains how lack of competition drives up drug prices for everyone

Wegovy and Ozempic are weight loss drugs that promise to transform the treatment of obesity, heart disease and other chronic conditions that afflict millions of Americans. But while everyone agrees these drugs have the potential to transform lives, no one can agree on how best to pay for them.

The Conversation

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Kentucky attorney general targets another big pharmacy benefit manager in opioid-related lawsuit

Kentucky’s attorney general has expanded an opioid-related lawsuit to target another pharmacy benefit manager

International Business Times

Outgoing Congress Still Has Time To Act On PBM Reform

Congress and President Joe Biden can address the problem of PBMs -- Pharmacy Benefit Managers -- by passing two bipartisan reforms during the current "lame duck" legislative session.

Fortune

Elon Musk and Bernie Sanders say they agree on one thing—cheaper Ozempic

Novo Nordisk is investing $30 billion to expand production, but middlemen are pocketing 74 cents of every dollar it makes in sales.

Top News

FTC Sues Pbms Over Soaring Insulin Prices

FTC lawsuit targets major PBMs for inflating insulin prices, impacting patients and drug costs. Debate over drug pricing and PBM role in healthcare system ...

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

High insulin prices spur a federal lawsuit against three pharmacy benefit managers

The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the price of insulin soar for patients

Roll Call

TRICARE becomes part of fight over pharmacy benefit managers - Roll Call

Lawmakers question whether the decision to renew Express Scripts as TRICARE's pharmacy benefit manager is a wise decision.

Fortune

Biden's plan to save money on Medicare drugs risks leaving shelves empty, pharmacists say

Biden is campaigning on cutting drug costs for Medicare patients, but independent pharmacists say one strategy makes it unaffordable to keep some brand-name medicines in stock.

The Independent UK

Rural pharmacies fill a health care gap in the US. Owners say it's getting harder to stay open

Rural pharmacies can be a touchstone for their communities

Top News

US Pharmacy Benefit Managers Facing Scrutiny

Learn about the controversies surrounding US pharmacy benefit managers (PBMs) and the need for increased regulation and transparency in the healthcare system.

Fortune

Mark Cuban’s Cost Plus Drugs will begin manufacturing its own medications this week

The "Shark Tank" investor and Cost Plus Drugs cofounder Dr. Alex Oshmyansky participated in a White House health care roundtable.

Roll Call

The inescapable ad campaign for a wonky drug policy debate - Roll Call

A seven-figure, yearlong PhRMA ad campaign has taken a very wonky policy debate mainstream — and it's made a longtime actor a familiar face.

1 2

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.